Cargando…

Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma

PURPOSE: Stereotactic body radiotherapy (SBRT) takes advantage of low α/β ratio of prostate cancer to deliver a large dose in few fractions. We examined clinical outcomes of SBRT using CyberKnife for the treatment of low- and intermediate-risk prostate cancer. MATERIALS AND METHODS: This study was b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Hun Jung, Phak, Jeong Hoon, Kim, Woo Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society for Radiation Oncology 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207371/ https://www.ncbi.nlm.nih.gov/pubmed/27306777 http://dx.doi.org/10.3857/roj.2015.01571

Ejemplares similares

Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost as post-external beam radiotherapy versus conventionally fractionated external beam radiotherapy for localized prostate cancer
por: Phak, Jeong Hoon, et al.
Publicado: (2016)

Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer
por: Kim, Hun Jung, et al.
Publicado: (2015)

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer
por: Anwar, Mekhail, et al.
Publicado: (2016)

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
por: Ju, Andrew W, et al.
Publicado: (2013)

Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma
por: Jeong, Bae-Kwon, et al.
Publicado: (2015)

Hypofractionated Radiotherapy in Localized, Low–Intermediate-Risk Prostate Cancer: Current and Future Prospectives
por: Lo Greco, Maria Chiara, et al.
Publicado: (2023)

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
por: Kishan, Amar U., et al.
Publicado: (2019)

Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer
por: Oermann, Eric K, et al.
Publicado: (2011)

Stereotactic Body Radiotherapy as Treatment for Organ Confined Low- and Intermediate-Risk Prostate Carcinoma, a 7-Year Study
por: Katz, Alan Jay, et al.
Publicado: (2014)

Low Incidence of Fatigue after Hypofractionated Stereotactic Body Radiation Therapy for Localized Prostate Cancer
por: Dash, Chiranjeev, et al.
Publicado: (2012)

Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR)
por: Nicolae, Alexandru, et al.
Publicado: (2015)

Evaluation of efficacy and safety of robotic stereotactic body radiosurgery and hypofractionated stereotactic radiotherapy for vertebral metastases
por: Księżniak-Baran, Dorota, et al.
Publicado: (2015)

CyberKnife multisession stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for perioptic meningiomas: intermediate-term results and radiobiological considerations
por: Conti, Alfredo, et al.
Publicado: (2015)

Hypofractionated Radiotherapy in Intermediate-Risk Prostate Cancer Patients: Long-Term Results
por: Valeriani, Maurizio, et al.
Publicado: (2022)

Hypofractionated stereotactic radiotherapy for large arteriovenous malformations
por: Wang, Huan-Chih, et al.
Publicado: (2012)

Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO)
por: Pasquier, David, et al.
Publicado: (2017)

Comparative evaluation of hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate and high risk prostate cancer
por: Soni, Abhishek, et al.
Publicado: (2022)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression
por: Kil, Whoon Jong, et al.
Publicado: (2013)

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer: Toxicity and quality of life assessment
por: Rucinska, Monika, et al.
Publicado: (2016)

Clinical outcomes of stereotactic body radiotherapy for spinal metastases from hepatocellular carcinoma
por: Lee, Eonju, et al.
Publicado: (2015)

Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
por: Shibamoto, Yuta, et al.
Publicado: (2016)

Intracranial chordoma: radiosurgery, hypofractionated stereotactic radiotherapy and treatment outcomes
por: Napieralska, Aleksandra, et al.
Publicado: (2021)

Stereotactic Body Radiotherapy for Prostate Cancer
por: Parikh, Neil R., et al.
Publicado: (2020)

The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases
por: Gutschenritter, Tyler, et al.
Publicado: (2020)

Cost-effectiveness analysis of ultra-hypofractionated radiotherapy and conventionally fractionated radiotherapy for intermediate- to high-risk localized prostate cancer
por: He, Jiaoxue, et al.
Publicado: (2023)

Image-Guided Hypofractionated Radiotherapy in Low-Risk Prostate Cancer Patients
por: Valeriani, Maurizio, et al.
Publicado: (2014)

Review of Hypofractionated Radiotherapy for Prostate Cancer
por: Spyropoulou, Despina, et al.
Publicado: (2012)

The Role of Hypofractionated Radiotherapy in Prostate Cancer
por: Benjamin, Linus C., et al.
Publicado: (2017)

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes
por: Freeman, Debra E, et al.
Publicado: (2011)

Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results
por: Aluwini, Shafak, et al.
Publicado: (2013)

Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer
por: Boyer, Matthew J., et al.
Publicado: (2017)

Stereotactic body radiotherapy with CyberKnife(®) System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial
por: Borzillo, Valentina, et al.
Publicado: (2023)

Linear Accelerator-Based Stereotactic Radiotherapy for Low-Grade Meningiomas: Improved Local Control With Hypofractionation
por: Wegner, Rodney E, et al.
Publicado: (2019)

Outcomes of stereotactic body radiotherapy for unresectable primary or recurrent cholangiocarcinoma
por: Jung, Da Hoon, et al.
Publicado: (2014)

Stereotactic Body Radiation Therapy for Low- and Low-Intermediate-Risk Prostate Cancer: Is there a Dose Effect?
por: Katz, Alan J., et al.
Publicado: (2011)

Hypofractionated Stereotactic Radiotherapy for Patients with Intracranial Meningiomas: impact of radiotherapy regimen on local control
por: Meniai-Merzouki, F., et al.
Publicado: (2018)

Reproducibility and geometric accuracy of the fixster system during hypofractionated stereotactic radiotherapy
por: Lindvall, Peter, et al.
Publicado: (2008)

Hypofractionated stereotactic radiotherapy for brain metastases larger than three centimeters
por: Jiang, Xue-song, et al.
Publicado: (2012)

Cone-beam computed tomography in hypofractionated stereotactic radiotherapy for brain metastases
por: Ingrosso, Gianluca, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8j56gapfsc5k7knkkuvf0g00ge